阅读说明：本技术 一种msc用于抑制病毒复制的应用 (Application of MSC (Mobile switching center) in inhibiting virus replication ) 是由 王文军 黄险峰 王明 康禹 欧阳智华 王程 李学林 李珊 于 2020-05-23 设计创作，主要内容包括：本发明具体公开了一种MSC用于抑制病毒复制的应用,尤其是MSC用于抑制病毒性感染患者病毒复制的应用,涉及生物医药工程技术领域。本发明通过将所制备的MSC制剂加入到MSC治疗组中对病毒性感染患者进行联合治疗,使得MSC治疗组愈后患者核糖体基因表达能够恢复到健康人员的水平,因此通过MSC治疗组治愈后能够对病毒复制进行有效抑制。(The invention specifically discloses an application of MSC (Mobile switching center) in inhibiting virus replication, in particular to an application of MSC in inhibiting virus replication of a virus infection patient, relating to the technical field of biomedical engineering. The prepared MSC preparation is added into the MSC treatment group to carry out combined treatment on the virus infected patients, so that the ribosome gene expression of the patients can be restored to the level of healthy people after the MSC treatment group is cured, and virus replication can be effectively inhibited after the MSC treatment group is cured.)

1. Use of an MSC for inhibiting viral replication.

2. Use of the MSC of claim 1 for inhibiting viral replication, wherein the MSC is used for inhibiting viral replication in a virally infected patient.

3. The use of MSCs as claimed in claim 2 for inhibiting viral replication, wherein the use of MSCs for inhibiting viral replication in a virally infected patient comprises the specific steps of:

s1, preparing an MSC preparation;

s2, screening patients with viral infection and bringing the screened patients with viral infection into an MSC treatment group for combination treatment;

and S3, sampling and analyzing the peripheral blood mononuclear cell sample of the patient after the recovery, thereby obtaining the virus replication condition of the patient after the recovery.

4. The use of the MSCs of claim 3 for inhibiting viral replication, wherein the preparation of said MSC is prepared by a method comprising:

s11, collecting an umbilical cord, placing the umbilical cord in a culture dish, and then cleaning an umbilical cord tissue through physiological saline;

s12, cutting the cleaned umbilical cord tissue into small tissue blocks and planting the small tissue blocks in a culture dish for culture;

s13, removing the culture solution in the culture dish, cleaning the culture dish by using normal saline, adding pancreatin for digestion, adding a stop solution to stop digestion until the cells in the culture dish are digested, transferring the cell suspension into a centrifuge tube for centrifugation, discarding supernatant, resuspending the cells by using a proper amount of culture solution, counting, and finally planting the cell suspension into a new culture dish for culture according to a counting result;

s14, removing the culture solution in the new culture dish in the step S13, then washing with normal saline, adding pancreatin for digestion, adding a stop solution to stop digestion after cell digestion in the culture dish is finished, filtering with a cell sieve, transferring the filtered cell suspension into a centrifuge tube, counting, centrifuging, discarding supernatant, preparing cell preparation suspension, adding cell preparation suspension for cell suspension resuspension, transferring the cell suspension into a transfer bag, and putting the transfer bag into a low-temperature environment for taking, thereby completing preparation of the MSC preparation;

s15, carrying out qualification detection on the MSC preparation prepared in the step S14.

5. The use of the MSC of claim 4 for inhibiting viral replication, wherein the combination therapy in the MSC treatment group is: the MSC preparation prepared in step S1 is incorporated into an MSC treatment group to be used in combination for patients with viral infection.

6. The use of the MSC of claim 5 for inhibiting viral replication, wherein the combination in a combination therapy is: MSC preparation is added in the original treatment scheme as a unique interference factor, and the condition of the combined medicine is tracked and recorded in the process of combined treatment.

7. The use of the MSC of claim 6 for inhibiting viral replication, wherein the post-healing patients comprise virally infected patients cured by the MSC-treated group and virally infected patients not cured by the MSC-treated group.

8. The use of the MSC of claim 7 for inhibiting viral replication, wherein step S3 is performed by analyzing the mononuclear cell sample of the peripheral blood by single cell sequencing to obtain the viral replication status of the patient after healing.

Technical Field

The invention relates to the technical field of biomedical engineering, in particular to application of MSC (mesenchymal stem cell) in inhibiting virus replication.

Background

Viral infection refers to infectious diseases caused by viruses that can parasitize and propagate in the human body and cause diseases. Mainly shows general toxic symptoms such as fever, headache, general malaise and the like and local symptoms caused by inflammatory injury caused by virus hosts and invading tissues and organs. Viral infections of the human body are classified into recessive infections, dominant infections, and lentivirus infections. In most cases, the infection is recessive (after the infection of the human body with the virus, no symptoms appear, but specific antibodies can be produced). A few are dominant infections (meaning that symptoms appear after the human body is infected with viruses). The majority of the dominant infections are acute infections, the onset of diseases is acute, the course of diseases is short, and the minority of the dominant infections are latent infections (such as herpes virus infections) and chronic infections (such as hepatitis B virus infections). At present, the virus infection diseases lack specific treatment, mainly support and symptomatic treatment, and antiviral drugs and hormone treatment cannot play an effective treatment role. And viral infections (such as influenza, SARS, MERS and ebola) spread rapidly in humans, posing a significant threat to human health. Especially, the novel coronavirus which is outbreaked worldwide in 2020 causes serious loss to human health and economy.

The etiology of COVID-19 has been shown to be a novel coronavirus, now known as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At present, no specific medicine or vaccine aiming at the virus is successfully developed, and the appearance of SARS-CoV-2 brings a difficult treatment dilemma to clinicians. Most infected patients exhibit non-specific symptoms such as fever, dry cough, and fatigue. The prognosis of most patients is good, and some patients with severe disease can rapidly develop acute respiratory distress syndrome, septic shock, metabolic acidosis, blood coagulation dysfunction and even die. The deterioration of the patient's condition may be due to a cytokine storm in the body, and since SARS-CoV-2 is a novel strain that causes a global pandemic, there is an urgent need for effective targeted therapies, including antiviral and immunotherapy. Currently, although many clinical trials have begun, there is currently no effective antiviral or immunomodulatory therapy for the treatment of SARS-CoV-2.

Clinical studies have found that MSC is an effective tool for treating diseases associated with Human Immunodeficiency Virus (HIV) immune abnormality, Hepatitis B Virus (HBV) chronic hepatitis, influenza virus Acute Lung Injury (ALI), and the like. Mesenchymal Stem Cells (MSCs) refer to a group of pluripotent stem cells with diverse differentiation potential that have differentiated into osteoblasts, chondroblasts and adipoblasts. They are derived from immature embryonic connective tissues of mesoderm and ectoderm in early embryonic development stage, and can differentiate into various tissue cells such as fat, bone, cartilage, muscle, tendon, ligament, nerve, liver, cardiac muscle, endothelium and even blood under specific induction conditions in vitro and in vivo. Clinical studies have found that MSC is an effective tool for treating diseases associated with Human Immunodeficiency Virus (HIV) immune abnormality, Hepatitis B Virus (HBV) chronic hepatitis, influenza virus Acute Lung Injury (ALI), and the like. MSCs have low immunogenicity as well as significant and extensive immune-regulatory functions. MSCs do not express co-stimulatory molecules such as CD40, CD80, and CD86, as well as MHC-class II molecules. The T cell inhibitory effect of MSCs is not restricted by MHC, i.e. the effect on autologous and allogeneic T cells is similar. The antiviral response is critical to eradicate the virus and prevent the development of virus-related diseases. MSC-derived interferon-is thought to counteract the immunosuppressive effects of MSCs by mediating a partial cytotoxic response during viral infection. Therefore, when using MSCs as regenerative medicine, it is very important to recognize the dual role of MSCs in fighting viral infections of the immune system.

Since influenza viruses use both viral and host cell proteins to control selective translation of viral mRNA during infection, heterogeneity in ribosomal protein composition leads to the formation of "special ribosomes" with different selectivity, preferentially translating specific mRNAs21, and expression of specific ribosomal proteins can lead to a change in the translated mRNA profile without affecting overall protein synthesis. In view of the above, the present invention provides an application of MSC for inhibiting virus replication, in particular an application of MSC for inhibiting virus replication in a patient with viral infection.

Disclosure of Invention

The invention aims to provide application of MSC (mesenchymal stem cell) in inhibiting virus replication, in particular application of MSC in inhibiting virus replication of a virus infected patient.

The application of MSC in inhibiting virus replication of virus infected patient includes the following steps:

s1, preparing an MSC preparation;

s2, screening patients with viral infection and bringing the screened patients with viral infection into an MSC treatment group for combination treatment;

and S3, sampling and analyzing the peripheral blood mononuclear cell sample of the patient after the recovery, thereby obtaining the virus replication condition of the patient after the recovery.

Preferably, the preparation method of the MSC preparation comprises:

s11, collecting an umbilical cord, placing the umbilical cord in a culture dish, and then cleaning an umbilical cord tissue through physiological saline;

s12, cutting the cleaned umbilical cord tissue into small tissue blocks and planting the small tissue blocks in a culture dish for culture;

s13, removing the culture solution in the culture dish, cleaning the culture dish by using normal saline, adding pancreatin for digestion, adding a stop solution to stop digestion until the cells in the culture dish are digested, transferring the cell suspension into a centrifuge tube for centrifugation, discarding supernatant, resuspending the cells by using a proper amount of culture solution, counting, and finally planting the cell suspension into a new culture dish for culture according to a counting result;

s14, removing the culture solution in the new culture dish in the step S13, then washing with normal saline, adding pancreatin and digesting until the cells in the culture dish are digested, adding a stop solution to stop the digestion, filtering with a cell sieve, transferring the filtered cell suspension into a centrifuge tube, counting and centrifuging to discard the supernatant, preparing cell preparation suspension, adding cell preparation suspension to resuspend the cells, transferring the cell suspension into a transfer bag, and putting the transfer bag into a low-temperature environment for taking, thereby completing the preparation of the MSC preparation;

s15, carrying out qualification detection on the MSC preparation prepared in the step S14.

Preferably, the combination therapy in the MSC treatment group is: the MSC preparation prepared in step S1 is incorporated into an MSC treatment group to be used in combination for patients with viral infection.

Preferably, the combination in the combination therapy refers to: MSC preparation is added in the original treatment scheme as a unique interference factor, and the condition of the combined medicine is tracked and recorded in the process of combined treatment.

Preferably, the patients after healing include patients with viral infection cured by the MSC-treated group and patients with viral infection not cured by the MSC-treated group.

Preferably, the step S3 is to analyze the peripheral blood mononuclear cell sample by single cell transcriptome sequencing, so as to obtain the virus replication status of the patient after healing.

Compared with the prior art, the prepared MSC preparation is applied to MSC treatment groups to carry out combined treatment on patients with viral infection, so that the ribosome genes RPS4Y1 and RPS26 of patients after MSC treatment groups are cured can be restored to the level close to that of healthy groups, and as the ribosome genes RPS4Y1 and RPS26 are both involved in the formation of 40S subunits and are rich in a virus mRNA translation pathway (R-HSA-192823), when the disorder of the ribosome genes RPS4Y1 and RPS26 is helpful for virus replication, the patients after MSC treatment groups are cured can effectively inhibit the virus replication in vivo.

Drawings

FIG. 1 is a flow chart of an application of MSC for inhibiting viral replication in a patient with viral infection,

figure 2 is a flow chart of a method of preparing the MSC formulation of the present invention,

FIG. 3 is a graph showing the comparison of the expression levels of ribosomal genes in healthy subjects, patients after the MSC-treated group was cured and patients without the MSC-treated group in the present invention,

FIG. 4 is a flowchart of the inhibition of viral replication in vivo by the ribosomal genes in the present invention.

Detailed Description

In order to make the technical solutions of the present invention better understood, the present invention is further described in detail below with reference to the accompanying drawings.

It should be noted that the original treatment plan in the present invention refers to a treatment plan adopted in a novel coronavirus pneumonia diagnosis and treatment plan issued by the office of the national Health and care committee and the office of the national traditional Chinese medicine administration, MSC + represents an MSC treatment group, MSC-represents a non-MSC treatment group, and Health represents a healthy group.

As shown in fig. 1, in order to study the application of MSC for inhibiting virus replication, the present invention provides a specific step of the application of MSC for inhibiting virus replication in a patient with viral infection, comprising:

s1, preparing an MSC preparation;

s2, screening patients with viral infection and bringing the screened patients with viral infection into an MSC treatment group for combination treatment;

s3, sampling and analyzing the peripheral blood mononuclear cell sample of the patient after the recovery, thereby obtaining the virus replication inhibition condition of the patient after the recovery.

As shown in fig. 2, wherein the preparation method of the MSC preparation comprises:

s11, collecting an umbilical cord, placing the umbilical cord in a culture dish, and then cleaning an umbilical cord tissue through physiological saline;

s12, cutting the cleaned umbilical cord tissue into small tissue blocks and planting the small tissue blocks in a culture dish for culture;

s13, removing the culture solution in the culture dish, cleaning the culture dish by using normal saline, adding pancreatin for digestion, adding a stop solution to stop digestion until the cells in the culture dish are digested, transferring the cell suspension into a centrifuge tube for centrifugation, discarding supernatant, resuspending the cells by using a proper amount of culture solution, counting, and finally planting the cell suspension into a new culture dish for culture according to a counting result;

s14, removing the culture solution in the new culture dish in the step S13, then washing with normal saline, adding pancreatin for digestion, adding a stop solution to stop digestion after cell digestion in the culture dish is finished, filtering with a cell sieve, transferring the filtered cell suspension into a centrifuge tube, counting, centrifuging, discarding supernatant, preparing cell preparation suspension, adding cell preparation suspension for cell suspension resuspension, transferring the cell suspension into a transfer bag, and putting the transfer bag into a low-temperature environment for taking, thereby completing preparation of the MSC preparation;

s15, carrying out qualification detection on the MSC preparation prepared in the step S14.

In this embodiment, the MSC preparation is prepared from Human umbilical cord mesenchymal stem cells (hiuc-MSC), the preparation process is performed in a sterilized clean bench, instruments and consumables and the like required in the preparation process are sterilized with 75% alcohol, and the collection or cells in the culture dish and the specific operation process need to be labeled in detail in the preparation process; meanwhile, the stem cells can be frozen between the step S13 and the step S14, and if the frozen stem cells need to be revived before the step S14 is performed on the stem cell preparation, the stem cell freezing and reviving operations both belong to the prior art, and are not described in detail herein.

In this embodiment, the qualification testing of the MSC preparation further includes quality testing of the collected material, warehousing testing of the primary cell bank of the umbilical cord mesenchymal stem cells, and warehousing testing of the main cell bank of the umbilical cord mesenchymal stem cells, and the step and standard of the qualification testing are consistent with those of the conventional passing testing, which is not repeated here.

The combined treatment in the MSC treatment group refers to that the MSC preparation prepared in the step S1 is brought into the MSC treatment group and is used as a unique interference factor in an original treatment scheme to carry out combined medication on patients with viral infection, and meanwhile, the combined medication condition is tracked and recorded in the combined treatment scheme⁵-5×10⁸Cell number/ml, MSC preparation was administered by peripheral intravenous infusion throughout the MSC treatment group and was used several times. Wherein the number of times of use can be controlled between 1 and 10 times according to actual conditions.

In this example, we divided the selected common new coronary positive patients (i.e. SARS-CoV-2 virus infected patients) into two groups and used them as MSC treatment group samples and non-MSC treatment group samples (i.e. original treatment scheme), and then sample the peripheral blood mononuclear cells of the healed patients after the virus infected patients in the two groups of samples are cured, and in order to better illustrate the working principle and technical effect of the present invention, we simultaneously selected to sample the peripheral blood mononuclear cells of a corresponding number of healthy group personnel, and then analyzed the collected peripheral blood mononuclear cell samples by single cell sequencing and processed the analysis results, so as to obtain the ribosome gene expression relationship between the healed patients of the MSC treatment group and the healthy group personnel (see Table 1) and the ribosome gene expression relationship between the healed patients of the non-MSC treatment group and the healthy group personnel (see Table 2), negative numbers corresponding to the values of avg _ logFC for the ribosomal gene in the MSC-treated and non-MSC-treated groups in tables 1 and 2 indicate that the gene is down-regulated relative to the healthy group. In other embodiments, other virally infected patients may be selected as samples for the MSC-treated group and the non-MSC-treated group.

TABLE 1 relationship of ribosomal gene expression between healthy group and MSC-treated group-healed patients

TABLE 2 relationship of ribosomal gene expression between healthy group and patients after recovery without MSC treatment

Meanwhile, a schematic diagram of ribosomal gene expression between the healed patients and the healthy group personnel is drawn according to the processing result data after single cell sequencing analysis (see fig. 3, the darker the color in the diagram indicates that the gene expression is higher), and as can be seen from fig. 3, the ribosomal gene RPS26 of the healed patients and the healthy group personnel of the MSC treatment group is basically consistent, while the ribosomal gene RPS26 of the healed patients and the healthy group personnel of the MSC treatment group are obviously reduced, meanwhile, the ribosomal gene RPS4Y1 of the healed patients and the healthy group personnel of the MSC treatment group are also basically consistent, and the ribosomal gene RPS4Y1 of the healed patients is obviously increased.

As can be seen from table 1, table 2 and fig. 3, in comparison with the healthy group, the ribosomal genes RPS4Y1 and RPS26 in the patients after healing without MSC treatment were significantly out-regulated, while the ribosomal genes RPS4Y1 and RPS26 in the patients after healing with MSC treatment were almost close to the normal level of the healthy group, and since both ribosomal genes RPS4Y1 and RPS26 are involved in the formation of 40S subunit and are functionally enriched in the viral mRNA translation pathway (R-HSA-192823) (as shown in fig. 4), the ribosomal genes RPS4Y1 and RPS26 in the patients after healing without MSC treatment were beneficial to the viral replication in the patients after being out-regulated, and the ribosomal genes RPS4Y1 and RPS26 in the patients after healing with MSC treatment were close to the normal level of the healthy group, so the viral replication in the patients could be effectively inhibited.

The use of an MSC of the present invention for inhibiting viral replication is described in detail above. The principles and embodiments of the present invention are explained herein using specific examples, which are presented only to assist in understanding the core concepts of the present invention. It should be noted that, for those skilled in the art, it is possible to make various improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications also fall within the scope of the claims of the present invention.